Efficacy and Safety Trial of Flexible Doses of Oral Ziprasidone in Children and Adolescents With Bipolar I Disorder

Stopped early · Phase 3 · Has a placebo group

Conditions studied: Bipolar Disorder

In brief

The purpose of this study is to determine if ziprasidone is safe and effective for the treatment of children and adolescents (ages 10-17) with bipolar I disorder (manic or mixed).

Key facts

Study ID
NCT02075047
Run by
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
People needed
171
Starts
2014-05-23
Expected to finish
2020-05-18
Last updated by the study team
2021-06-16

Who can join

Age: 10 and older, up to 17. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.